Gentherm Incorporated — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied filing text does not provide clear standalone fourth-quarter results. Gentherm develops automotive thermal-management and comfort products and patient temperature-management systems. Automotive generated about 96% of product revenue.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Product revenue | $1,204.7 million | $1,046.2 million |
| Gross margin | $273.7 million; 22.7% | $303.6 million; 29.0% |
| Operating income | $48.3 million; 4.0% of revenue | $115.0 million; 11.0% of revenue |
| Net income | $24.4 million | $93.4 million |
| Diluted EPS | $0.73 | $2.79 |
| Operating cash flow | $14.9 million | $143.1 million |
| Capital expenditures | $39.7 million | $38.5 million |
| Cash and equivalents at year-end | $153.9 million | $190.6 million |
| Total debt at year-end | $235.1 million | $38.8 million |
Revenue grew 15.2%, reflecting automotive volume, acquisitions, and lower annual price reductions and customer cost recoveries; foreign exchange partly offset the increase. Gross margin contracted as material, labor and transportation inflation, acquisitions, and exit-related inventory impairment increased costs. Operating income also reflected higher R&D and SG&A, acquisition costs, and impairment charges. The effective tax rate was 36.3%, versus 17.9% in 2021.
Operating cash flow fell sharply, with working-capital changes a major use of cash. Year-end inventory rose to $218.2 million from $159.5 million, and accounts receivable to $247.1 million from $183.0 million. Investing cash outflow was $239.9 million, including $205.5 million for acquisitions. Financing cash inflow was $189.9 million, including $207.0 million of borrowings.
The company had $264.9 million available under its $500 million revolving credit facility, which matures in 2027; the year-end drawn U.S. revolving balance was $232.0 million at 5.80%. Gentherm reported covenant compliance and said cash, available borrowings, factoring arrangements and operating cash flows should meet anticipated needs for at least 12 months. A 100-basis-point rate change would affect annual interest expense by an estimated $2.3 million.
Material changes and notable items
- Acquisitions: Acquired Alfmeier, an automotive lumbar, massage and valve-systems supplier, for $170.7 million, and Dacheng, a medical-equipment manufacturer, for $35.0 million. Alfmeier contributed $99.0 million of post-acquisition revenue and a $2.7 million net loss; Dacheng contributed $3.5 million of revenue and a $0.2 million net loss.
- Business exit: Approved a plan to exit non-automotive electronics. FY2022 included $9.4 million of inventory write-downs and $6.3 million of intangible-asset and property/equipment impairment. Management estimated total non-cash exit expenses of $13–18 million; a sale was under evaluation, with an 8–12 month wind-down contemplated if a sale was not pursued or successful.
- Customer concentration: Lear and Adient accounted for 16% and 15% of product revenue, respectively. Lear had acquired competing businesses and expressed an intent to expand thermal-comfort capabilities; the filing says the future effect on Gentherm is uncertain.
- Ukraine exposure: Products made at the Ukrainian facility represented approximately 8% of 2022 revenue, down from 11% in 2021. The facility was operating normally, but the company cited risks from the conflict, staffing, power interruptions and cross-border shipping.
Outlook, commentary and risks
Management cited ongoing uncertainty from supply constraints, inflation, customer production volatility, foreign exchange and geopolitical conditions, and warned that supply-chain disruption could materially affect performance. S&P Global Mobility forecast 3.4% growth in light-vehicle production across Gentherm’s key markets in 2023; this is an external forecast, not company revenue guidance. Gentherm anticipated FY2023 capital expenditures of approximately $60–70 million.
Management highlighted growth priorities in personalized thermal comfort, pneumatic comfort, battery performance and patient thermal solutions, supported by electronics and software. FY2022 automotive new-business awards were estimated at $1.793 billion in projected lifetime revenue, not firm orders or a revenue forecast. The Medical reporting unit’s estimated fair value exceeded carrying value by less than 10%; its valuation depends materially on projected 2023–2025 revenue CAGR of approximately 24% and margin expansion, creating impairment risk if launches, customer acceptance or results disappoint.
Other principal risks include automotive cyclicality and dependence on production schedules; semiconductor and other component shortages; inflation and limited ability to pass through costs; competition and customer insourcing; labor availability; acquisition integration; foreign currency exposure; product quality, recalls and medical-device regulation; cybersecurity; and debt covenants. The filing reports no material pending litigation. The auditor issued unqualified opinions on the financial statements and internal control; management and the auditor excluded Alfmeier and Dacheng from the FY2022 internal-control assessment during the first year after acquisition.
Important facts for investors to verify
- Whether automotive volume, pricing and input-cost recovery improve sufficiently to restore gross and operating margins.
- Whether operating cash flow recovers as inventory and receivables are managed, and whether planned capital spending remains within the $60–70 million range.
- Integration progress and returns from Alfmeier and Dacheng, including realization of expected growth and synergies.
- Progress and final costs of the non-automotive electronics exit, including any sale or wind-down outcome.
- Medical-segment performance against the growth and margin assumptions supporting its goodwill valuation.
- Developments in Lear’s competitive strategy, semiconductor availability, and the Ukraine facility and logistics contingency plans.
- Debt balances, interest expense, covenant headroom and availability under the revolving credit facility.